⚡ Decentralized clinical trials aim to reduce patient burden. Decentralized clinical trials can help make research more patient-centric. Tim explains the role of decentralization, "It's fair to say that that change management component is absolutely critical in terms of the decentralized adoption, and I think, when I look ahead in terms of decentralization, I see an amazing landscape for patients and the partnerships with EmVenio and also the kind of opportunities Thermo Fisher Scientific has in really driving forward unique and collaborative solutions for the better of the patient and really focusing on reducing that patient burden."⚡ We need to make clinical trials more patient-centric. Patient-centricity is key when it comes to improving participation in clinical trials and clinical research progress overall. Tim says, "As an industry, we talk about patient-centricity and I think we embrace significant patient-centricity by taking a research site with all the research professionals on board to the patient's home."⚡ Representation in clinical trials matters. Diversity is vital to preventing and treating diseases across race and gender. Thad says, "A couple of stats recently — there was one study we supported where of the 2,500 patients that EmVenio enrolled, 65% were from underrepresented populations, and so it really showed that value there. And what we're seeing more broadly is that across the studies we support, greater than 40% of the patients we're working with come from minority populations. And so, to contrast that against industry stats of around 10% to 20% as an average, we're offering more than double the ability to reach these populations that otherwise don't have access. So I think what we're seeing is that the results are really bearing on the value that we're bringing together."